Quantum BioPharma Ltd. (QNTM)
| Market Cap | 44.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -20.88M |
| Shares Out | 3.04M |
| EPS (ttm) | -13.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200,068 |
| Open | 14.60 |
| Previous Close | 14.55 |
| Day's Range | 14.02 - 15.40 |
| 52-Week Range | 2.70 - 23.81 |
| Beta | 1.47 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2025 |
About QNTM
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse ... [Read more]
News
Quantum BioPharma Clarifies It Has Not Changed Its Name
TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovat...
iNGENū CRO Partners with Quantum BioPharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS Patients
Study Aims to Expedite Potentially Transformative Therapies By Assessing Safety and Efficacy of FSD202 Study Aims to Expedite Potentially Transformative Therapies By Assessing Safety and Efficacy of F...
Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
Dr. Raza Bokhari, Company's Former CEO, Paid $2.35 Million USD in Non-Dilutive Cash to Cover Legal and Other Costs Determined in the Arbitral Award Over the Past 4 Years Dr. Raza Bokhari, Company's Fo...
Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.
TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovati...
Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome
TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a port...
Quantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple Sclerosis
TORONTO, May 20, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a port...
Quantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000
TORONTO, May 19, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that after receiving approval fro...
Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference
TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”) a biopharmaceutical company dedicated to building a portfo...
Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a port...
Quantum BioPharma Ltd. (QNTM) Business Update Conference Call Transcript
Call Start: 16:30 January 1, 0000 4:57 PM ET Quantum BioPharma Ltd. (NASDAQ:QNTM) Business Update Conference Call May 6, 2025, 04:30 PM ET Company Participants Zeeshan Saeed - Founder, Chief Executiv...
Quantum Biopharma Files Amended Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
To assist enquiries a copy of the amended complaint can be viewed by clicking the following link: Quantum Amended Court Claim
Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time
TORONTO, April 24, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”), today announced it will host a Business Update Conferen...
Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor
TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce the appointment of Kevin Malone...
Quantum BioPharma Corporate Update
Toronto, Ontario--(Newsfile Corp. - April 18, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company...
Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario
Awards in favour of Quantum BioPharma Totalling $180,000 upheld and is now due Awards in favour of Quantum BioPharma Totalling $180,000 upheld and is now due
Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico
Alcohol Detoxification and Anti-Hangover Beverage (Available on amazon.com and unbuzzd.com) to be Distributed by FUSION in Puerto Rico and Caribbean Region TORONTO, April 03, 2025 (GLOBE NEWSWIRE) --...
Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis
TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a por...
Quantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved Terms
TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”) is pleased to announce that it has closed the final tra...
Quantum BioPharma Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - March 30, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to bui...
Overlooked Stock: QNTM
Quantum's in the name but has no part of the business. Quantum BioPharma (QNTM) is up over 130% year to date but has fallen more than 50% off its all-time high.
Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern
Completion of unbuzzdTM Clinical Trial and Multiple Sclerosis Drug Lucid-21-302 Phase 1 Trial Advance Company's Pipeline of Products and Assets TORONTO, ONTARIO / ACCESS Newswire / March 28, 2025 / Qu...
Quantum BioPharma Continues to Grow Its Crypto Assets and Diversify Its Treasury With the Purchase of Another USD $1,500,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
TORONTO, March 20, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that after receiving approval f...
Quantum BioPharma Unaware of Any Material Change
Toronto, Ontario--(Newsfile Corp. - March 17, 2025) - At the request of the Canadian Investment Regulatory Organization, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (the "Company") w...
Quantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
TORONTO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated ...
Quantum Biopharma Engages Enterprise Canada and Empire Market Ventures to Lead Public Communications and Investor Awareness Programs
TORONTO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated ...